Clinical Trial Update: A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of AK105 (anti-PD-1) in metastatic nonsquamous non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)

Snippet

Sponsor: Akeso | Conditions: Lung Cancer Non-small Cell Stage IV | Phase 3 | Status: TERMINATED